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Abstract
Gene-targeting strategies based on nucleic acid have opened a new era with the develop‐
ment of potent and effective gene intervention strategies, such as DNAzymes, ribozymes,
small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), aptamers, decoys,
etc. These technologies have been examined in the setting of clinical trials, and several
have recently made the successful transition from basic research to clinical trials. This
chapter discusses progress made in these technologies, mainly focusing on Dzs and siR‐
NAs, because these are poised to play an integral role in antigene therapies in the future.
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1. Introduction
Over the past decade, it is known that the advent of oligonucleotide-based gene inactivation
agents have provided potential for these to serve as analytical tools and potential treatments
in a range of diseases, including cancer, infections, inflammation, etc. During this time, many
genes have been targeted by specifically engineered agents from different classes of small-
molecule nucleic-acid-based drugs in experimental models of disease to probe, dissect, and
characterize further the complex processes that underpin molecular signaling. Subsequently,
a number of molecules have been examined in the setting of clinical trials, and several have
recently made the successful transition from the bench to the clinic, heralding an exciting era
of gene-specific treatments. This is particularly important because clear inadequacies in
present therapies account for significant morbidity, mortality, and cost. The broad umbrella
of gene-silencing therapeutics encompasses a range of agents that include deoxyribozymes
(DNAzymes, Dzs), ribozymes, siRNAs, ASOs, aptamers, and decoys. This chapter tracks
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current movements in these technologies, focusing mainly on Dzs and siRNAs, because these
are poised to play an integral role in antigene therapies in the future.
2. DNAzymes
Among the gene-silencing technologies, Breaker and Joyce, in 1994, used an in vitro selection
method to identify a special Dz from a random pool of single-stranded DNA to catalyze Pb2+-
dependent cleavage of an RNA phosphodiester linkage [1]. Afterward, a number of Dzs were
created with the capacity to catalyze many reactions, including the cleavage of DNA or RNA,
the modification and ligation of DNA, and the metalation of porphyrin rings. However,
because of the low efficiency of RNA cleavage, they are not widely used for biological
applications except for 10-23 Dz [2]. The inherent catalytic RNA-cleaving property of Dzs has
been used with different mRNA targets as in vitro diagnostic and analytical tools, as well as
in vivo therapeutic agents.
2.1. The possible mechanisms and characteristics of DNAzymes
Dzs of the 10-23 subtype are single-stranded DNA catalysts that comprise a central cation-
dependent catalytic core of around 15 deoxyribonucleotides [ggctagctacaacga], and two
complementary binding arms of 6–12 nucleotides that are specific for each site along the target
RNA transcript [3]. As diagrammed in Figure 1, the enzyme binds the substrate through
Watson-Crick base pairing and cleaves a particular phosphodiester linkage located between
an unpaired purine and paired pyrimidine in the RNA. This results in the formation of 5’ and
3’ products, which contain a 2’, 3’-cyclic phosphate and 5’-hydroxyl terminus, respectively.
Even though the 10-23 Dz can cleave any RY junction, the reactivity of each substrate dinu‐
cleotide compared in the same background sequence with the appropriately matched DNA‐
zyme is found to follow the scheme AU = GU > GC >> AC. Murray et al. found that when the
target site core is an RC dinucleotide, the relatively poor activity could be enhanced up to 200-
fold by substituting deoxyguanine with deoxyinosine, which could effectively reduce the
strength of Watson-Crick pairing between bases flanking the cleavage site [4].
Due to the simple cleavage-site requirement, Dzs are capable of cleaving any particular
mRNAs for multiple turnover by appropriately designing the sequence in the binding arms.
Several features make Dzs attractive from a drug developmental viewpoint. For example, these
are inexpensive to synthesize, and their small size allows specificity. Moreover, DNAzymes
can be rendered more stable by structural modifications, such as phosphorothioate (PS)
linkages, locked nucleic acids (LNAs), and 3’-3’ inverted nucleotide end of the DNAzyme [5].
Enhanced biostability, low toxicity, affinity, and versatility suggest great promise for diag‐
nostic and therapeutic applications [6]. Limitations thus far in the development of DNAzymes
as novel therapeutics have been delivery and biodistribution, which revolve around poor
cellular uptake and stability. Delivery systems depend on the route of administration and the
target site. Moreover, an ideal delivery system would facilitate rapid and efficient distribution
to the site of action, stability, low toxicity, and efficacy.
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2.2. DNAzymes delivery systems – Past to present
As in all nucleic-acid-based reagents, efficient drug delivery systems (DDSs) to deliver the Dzs
to targeting site are highly needed. Furthermore, by adopting DDSs, it could be helpful to solve
the obstacles about DNAzymes’ stability, biological effects, and toxicity. Several seminal
studies have demonstrated that certain DNAzyme delivery systems can efficiently encapsulate
DNAzymes and transfect them into cells without clear toxicity. The attempt first involved the
microspheres of co-polymers poly (lactic acid) and poly (glycolic acid) (PLGA), which
encapsulated the Dzs. PLGA microspheres are able to achieve biphasic release and sustained
accumulation of the Dzs [7]. In a second delivery system, a chimeric aptamer–DNAzyme
conjugate was generated for the first time using a nucleolin aptamer (NCL-APT) and survivin
Dz (Sur_Dz). This conjugate could be used as a specific gene-targeting therapy to kill the
targeted cancer cells [8]. A third delivery system is developed and studied based on the cationic
liposomal formulation technology. Li et al. reported the effect of a c-Jun targeted DNAzyme
(Dz13) in a rabbit model of vein graft stenosis after autologous transplantation in a cationic
liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-
dioleoyl- snglycero-3-phosphoethanolamine (DOPE). Dz13/DOTAP/DOPE allows sufficient
uptake by the veins and reduces SMC (smooth muscle cell) proliferation and c-Jun protein
expression in vitro. Meanwhile, a Phase I clinical trial has indicated that it is safe and well
tolerated after local administration in skin cancer patients [9]. Finally, due to their low toxicity
and no side effects, nanoparticulate systems have spread rapidly and could significantly
enhance the efficacy of tumoricidal Dzs. Marquardt et al. found that c-Jun targeted Dz13
delivered in this manner is capable of enhanced skin penetration efficiency and cellular uptake
with a high reduced degradation of Dz13 in vitro [10]. These results indicate that, with more
suitable delivery approaches, the biological effects of Dzs would be further increased, and the
Dzs could be applied to new subject areas.
2.3. Application of DNAzymes in vivo and in vitro
Increasing evidence indicates the efficacy and potency of DNAzymes in vivo and in vitro in a
range of disease settings, allowing characterization of key pathogenic pathways and their
Figure 1. Secondary structure of the 10-23 DNAzyme–substrate complexes. The 10-23 DNAzyme consists of two varia‐
ble binding arms, designated arm I and arm II, which flank a conserved 15 base unpaired motif that forms the catalytic
core. The only requirement of the RNA substrate is for a core sequence containing an RY junction.
Small-molecule Nucleic-acid-based Gene-silencing Strategies
http://dx.doi.org/10.5772/62137
139
potential use as therapeutic agents (Table 1). DNAzymes have been widely applied as a new
interference strategy in the treatment of many conditions, including cancer, viral diseases, and
vein graft stenosis. For instance, Dz13 targeting the transcription factor c-Jun has shown
promise in experimental models of mice infected with H5N1 virus via reducing H5N1
influenza virus replication and decreasing expression of pro-inflammatory cytokines [11].
Furthermore, Dz13/DOTAP/DOPE reduces SMC proliferation and c-Jun protein expression in
vitro, and inhibits neintima formation after end-to-side transplantation, which may potentially
be useful to reduce graft failure [9]. Likewise, Cai et al. demonstrated that safe and well-
tolerated Dz13 could inhibit tumor growth and reduce lung nodule formation in a model of
metastasis [12].
Target Summary Description on Biological Effects(In Vitro and In Vivo) Refs.
LMP1
·Inhibiting proliferation and metastasis
·Promoting apoptosis
·Enhancing radiosensitivity
[13-15]
Egr-1 ·Inhibiting proliferation and metastasis·Suppressing tumor growth [16]
MMP-9 ·Inhibiting invasion and metastasis·Suppressing tumor growth [17, 18]
IGF-II ·Inhibiting proliferation·inducing caspase-dependent apoptosis [19]
survivin ·Inhibiting proliferation·Promoting apoptosis [8]
β-integrin ·Inhibiting invasion and metastasis·Blocking angiogenesis [20]
VEGFR-1 ·Blocking angiogenesis·Suppressing tumor growth [21]
DNMT1 ·Inhibiting proliferation [22]
Bcl-XL ·Promoting apoptosis·Enhancing Taxol chemosensitivity [23]
c-Jun
·Inhibiting proliferation
·Restraining virus replication and host inflammation
·Suppressing tumor growth
[9, 11, 12]
BCR-ABL T315I ·Overcoming imatinib resistance based on BCR-ABL T315IMutation [24]
EGFR T790M ·Overcoming EGFR T790M mutant-based TKI resistance [25]
TXNIP ·Attenuating oxidative stress, renal fibrosis, and collagendeposition [26]
Table 1. In vivo and in vitro applications of 10-23 DNAzymes
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As is well known, treatment resistance is one of the leading causes of tumor recurrence. We
have recently evaluated Dz1 targeting latent membrane protein 1 (LMP1) in the setting of
nasopharyngeal carcinoma model and demonstrated that injected intratumorally DZ1 with
fuGENE 6 in nude mice inoculating LMP1-positive cells resulted in a significant inhibition of
tumor growth and an enhanced radiosensitivity. Dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) showed that DZ1 reduces the angiogenesis and microvascular
permeability [13]. Other studies have used DNAzymes to target the other key genes in cancer
therapy. DNAzyme targeting the Bcl-XL gene significantly sensitized a panel of cancer cells
to apoptosis and further to reverse the chemoresistant phenotype [23]. Due to a secondary
mutation at T790M in the epidermal growth factor receptor (EGFR), most of nonsmall-cell lung
cancer (NSCLC) patients will eventually develop resistance to tyrosine kinase inhibitors (TKIs)
treatment. Allele-specific silencing of EGFR T790M expression and downstream signaling by
DNAzyme DzT could suppress the growth of xenograft tumors derived from H1975TM/LR cells,
indicating that DzT is capable of overcoming EGFR T790M mutant-based TKI resistance [25].
In a similar way, Kim et al. developed the DNAzyme that specifically targets the site of the
point mutation (T315I), conferring imatinib resistance in BCR–ABL mRNA. Cleavage of T315I-
mutant ABL mRNA by DNAzyme could significantly induce apoptosis and inhibit prolifera‐
tion in imatinib-resistant BCR-ABL-positive cells [24].
2.4. DNAzymes in clinical trials
The favorable properties of 10-23 Dzs, such as their enhanced biological stability, negligible
side effects, and lack of immunogenicity, have paved the way for Dzs to enter clinical trials
[17]. Up to now, Dzs to three targets have been undergoing clinical trials and at least one of
them has proved its therapeutic efficacy in Phase II trials (Table 2). These results further show
the potential of Dzs therapeutic approach for the treatment of diseases and represent a major
advance in this field.
As we have found that LMP1-targeted Dz1 could effectively inhibit the growth and enhance
the radiosensitivity of NPC cells both in vivo and in vitro, we investigated the antitumor and
radiosensitizing effects of Dz1 in NPC patients for the first time [27]. Being safe and well
tolerated, a randomized and double-blind clinical study was conducted in 40 NPC patients,
who received Dz1 or saline intratumorally in conjunction with radiation therapy. In a 3-month
follow-up, compared with the saline control group, the mean tumor regression and undetect‐
able EBV-DNA copy number in the DZ1 group is significantly higher. Molecular imaging
analysis found that Dz1 was tested to accelerate the decline of Ktrans, generally recognized as a
marker of tumor blood flow and permeability [28].
The nuclear transcription factor c-Jun is preferentially expressed in a range of cancers. Dz13
cleaves at the G1311U junction in human c-jun mRNA and exerts its antitumor activity via
induction of apoptosis, inhibition of angiogenesis, and the induction of adaptive immunity
[11]. A phase I first-in-human trial is conducted to determine the safety and tolerability of Dz13
in nine patients with basal-cell carcinoma (BCC), who received a single intratumoral injected
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dose of Dz13 (10, 30, or 100 ìg) [29]. Followed-up over four weeks, c-Jun expression is reduced
in all nine participants. Meanwhile, Dz13 could significantly promote apoptosis and stimulate
inflammatory and adaptive immune responses in the tumors. Among the participants, five
patients have a reduction in histological tumor depth. These results indicated that Dz13
possibly could represent a future treatment option for BCC prior to excision by surgery.
The transcription factor GATA-3 plays an important role in the regulation of Th2-mediated
immune mechanisms such as in allergic bronchial asthma, and the DNAzyme hgd40 has been
shown to specifically and selectively reduce expression of GATA-3 mRNA. Turowska et al.
found that hgd40 is evenly distributed in inflamed asthmatic mouse lungs within minutes after
single dose application, and could slowly eliminate from lung tissue with the goal to minimize
accumulation and to ensure continued exposure for efficacy [32]. Safety pharmacology studies
showed that with no observable adverse event, hgd40 has a highly favorable toxicity profile
when administered by aerosol inhalation at the therapeutic doses [33]. With good safety and
tolerability in the phase I program [31], a randomized, double-blind, placebo-controlled,
multicenter clinical trial of hgd40 was conducted in patients with allergic asthma, who had
biphasic early and late asthmatic responses after laboratory-based allergen provocation [30].
After each study drug administered by inhalation once daily for 28 days, hgd40 significantly
attenuates both late and early asthmatic responses and improves lung function. Moreover, the
Th2-regulated inflammatory responses are also attenuated.
Target Disease Phase Trial ID Refs.
LMP1 Nasopharyngeal carcinoma Phases I/II Completed NCT01449942 [27, 28]
c-Jun
Nodular basal-cell
carcinoma
Melanoma with satellite or
in-transit metastasis
Phases I Completed
Phase I/Ib Ongoing
ACTRN12610000162011
ACTRN12613000302752 [29]
GATA-3 Asthma Phases I Completed NCT01470911 [30-33]
Atopic dermatitis
Phases I Completed
Phases I Completed
Phases II Completed
Phase IIa Completed
Phases I Completed
NCT01554319
NCT01577953
NCT01743768
EUCTR2012-003570-77-DE
NCT02079688
Phases IIa Ongoing
Ulcerative colitis
Chronic obstructive
pulmonary disease
Phases I/II Ongoing
Phase IIa Pending
NCT02129439
DRKS00006087
Atopic eczema Phase IIa Ongoing EUCTR2013-001091-38-DE
Table 2. Clinical trials of DNAzymes in anti-diseases therapy
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These studies, taken together, further demonstrate the potential use of DNAzymes as gene-
targeting drugs. As Dzs are safe and well tolerated in humans, there is a good chance that we
may witness the Dzs reaching the clinic in the near future.
3. Small interfering RNA
Small interfering RNA (siRNA), first discovered in plants and Caenorhabditis elegans and later
in mammalian cells, is a member of a family of noncoding RNAs (ncRNAs) that affect and
regulate gene transcriptional and posttranscriptional silencing [34]. This sequence-specific
gene-silencing phenomenon could cause mRNA to be effectively broken down after tran‐
scription, resulting in no obvious translation. SiRNA represents an emerging therapeutic
approach against diseases for in vivo and in vitro studies, and along with novel drug delivery
techniques, the challenge of siRNA-based therapeutics is only now being optimized. These
discoveries led to a surge in interest in harnessing siRNA for biomedical research and drug
development.
3.1. The possible mechanisms and challenges of siRNAs
SiRNAs, synthetic mediators of RNA interference (RNAi), are basically dsRNA molecules
designed specifically to silence expression of target genes. Cytoplasmic dsRNA molecules are
considered unusual and are substrate for endonuclease Dicer, an RNase III family member.
Vertebrate-specific TAR (HIV trans-activator RNA) RNA-binding protein (TRBP) and protein
kinase R-activating protein (PACT) help Dicer to identify and dice dsRNA into about 21 bp
fragments with 2 nucleotides overhangs at each end, generating the siRNA. Then recognized
by an important enzyme Argonaute 2 (AGO2), siRNA of 21-23 nucleotides are incorporated
into an RNA-induced silencing complex (RISC). RNA helicases unwind the double-stranded
siRNA. The sense strand of the double-stranded siRNA is cleaved during the formation of the
RISC complex, and the antisense strand guides RISC to the complementary target mRNA,
which is rapidly degraded by RISC (Figure 2) [35, 36].
Though siRNAs can efficiently silence target gene expression in a sequence-specific manner,
many challenges, including rapid degradation, poor cellular uptake, off-target effects and
immune response, need to be addressed in order to carry these molecules into clinical trials
[37, 38]. For example, Chung et al. illustrated the underappreciated off-target effects of siRNA
gene knockdown technology. Hepatitis C Virus (HCV) depends on a core MOBKL1B (Mps
one binder kinase activator-like 1B)–NS5A peptide complex to complete its life cycle. However,
without the absence of MOBKL1B, siRNA of MOBKL1B still has off-target inhibitory effects
on virus replication [39]. Researchers have tried to develop modified method to reduce the
disadvantages. By using the default parameters in siDirect 2.0 Web server (http://siDir‐
ect2.RNAi.jp/), at least one qualified siRNA for >94% of human mRNA sequences in the RefSeq
database can be designed [40]. In addition, chemical modifications have been shown to protect
siRNAs from nuclease degradation without interfering with siRNA-silencing efficiency [37].
Thus, improvements in rational design strategies might have the potential to make the siRNAs
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more effective in the near future and to open the door to development of highly effective and
safe therapeutics for clinical applications.
3.2. SiRNAs delivery systems
Delivery of siRNAs to target tissues is impeded by many barriers at different levels. As possible
drugs in the near future, targeted delivery of siRNAs provides remarkable opportunities for
accelerating RNAi-based high-performance treatments. The success of siRNAs-based delivery
systems may be dependent upon uncovering a delivery route and sophisticated delivery
carriers. In this regard, Fujita et al. have reported a powerful platform (PnkRNA™ and
nkRNA®) to promote naked RNAi approaches through inhalation without delivery vehicles
in lung cancer xenograft models. This modified local drug delivery system could offer a
promising strategy for enhancing RNAi effects in cancer therapy [41]. In addition, with high
binding specificity, nucleic acid aptamer represents a different promising tool for selective
delivery siRNAs to cancer cells or tissues, resulting in increasing the therapeutic efficacy as
well as reducing toxicity [42]. Likewise, the latest studies in using cell-penetrating peptides
(CPPs) combined with molecular cargos, including liposomes, polymers, nanoparticles, and
so on, have indicated that for the delivery of siRNAs, the combination strategy can remit the
Figure 2. The process of siRNA-mediated degradation of target mRNA in eukaryotic cells. siRNA is recognized by
AGO2 and incorporated into the RISC. After that, RNA helicases unwind the double-stranded siRNA, and the anti‐
sense strand guides RISC to the complementary targeted mRNA, which is cleaved by RISC and rapidly degraded.
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reduced internalization efficiency caused by neutralization [43]. However, each transfection
process needs to be optimized because of cell density, siRNA concentration, transfection
reagents, etc.
3.3. Application of siRNAs – From the bench to the clinic
The discovery of RNA interference (RNAi) was approximately 20 years ago, and opened up a
new mechanism for gene-silencing therapeutics. Kim et al. evaluated the inhibition effect on
Notch1 expression by siRNA, and found that Notch1-targeted-siRNA could result in retarded
progression of inflammation, bone erosion, and cartilage damage in collagen-induced arthritis
(CIA) mice by efficiently inhibiting the expression of Notch1 in mRNA level [44]. Cao et al.
demonstrated that after silencing the expression of vascular endothelial growth factor (VEGF)
by siRNA, the number of living cells on the gel and the mucosa thickness are significantly
decreased in vivo, which indicated siRNA-targeting VEGF may be useful as a convenient
therapeutic option for chronic rhinosinusitis [45]. Similarly, VEGF-siRNA decreases the vessel-
forming ability and exhibited no testable cytotoxicity by significantly decreasing the expres‐
sion of VEGF mRNA and protein [46].
To date, given the progress of basic research, there are examples of clinical trial projects based
on RNAi technology against cancer and other diseases. SiRNA therapeutics is now well poised
to enter the clinical formulary as a new class of drugs in the near future. In an open-label phase
I/IIa study in the first-line setting of fifteen patients with nonoperable locally advanced
pancreatic cancer (LAPC), an siRNA drug (G12D) against KRAS, a Kirsten ras oncogene
homolog from the mammalian ras gene family, is well tolerated, safe, and demonstrated a
potential therapeutic efficacy to the patients enrolled, when combined with chemotherapy.
However, five participants experienced serious adverse events [47]. In addition, a recent
systematic analysis of a new RNAi therapeutic agent based on cationic lipoplexes containing
chemically stabilized siRNAs, called Atu027, which silences expression of protein kinase N3
in the vascular endothelium in patients with advanced solid tumors. In one case of 24 patients,
the study showed that Atu027 is tolerated up to 0.180 mg/kg, and no obvious dose-dependent
toxicities are observed [48]. Likewise, the results from another case of 34 patients showed that
Atu027 is safe in patients with advanced solid tumors, with 41% of patients having stable
disease for at least 8 weeks [49]. Also, because SYL040012 is an siRNA designed to specifically
silence β adrenergic receptor 2 (ADRB2) currently under development for glaucoma treatment
in vivo and in vitro [50], a phase I clinical trial of SYL040012 with 30 healthy subjects having
intraocular pressure (IOP) below 21 mmHg was conducted [51]. This trial found that admin‐
istration of SYL040012 over a period of 7 days significantly reduced IOP values regardless of
the dose used, was well tolerated locally and had no local or systemic adverse events. Thus,
taken together, these clinical studies conducted on siRNAs in the past few years indicate that
safe and effective target gene knockdown is achievable. Though targeting any individual gene
might lead to unanticipated clinical toxicity that could stop the development of any individual
siRNA drug, we anticipate a rapid expansion of clinical trials for multiple clinical indications.
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4. Antisense oligonucleotides
Antisense oligonucleotide, first recognized in 1978 by Zamecnik and Stevenson, is a small
synthetic piece of DNA (usually 15–18 mer in length) that can bind complementary RNA by
Watson-Crick base pairing. ASOs can target most RNA transcripts and have emerged as the
ideal therapeutic agents for a broad number of diseases [52, 53]. Upon binding to their target,
ASOs can modulate the intermediary metabolism of RNA by the recruitment of endogenous
RNase H1 to interfere with RNA function [54]. Human RNase H1 is a ubiquitous enzyme that
hydrolyzes the duplex formed between a DNA containing ssASO and target RNA through its
N-terminus RNA-binding domain. In order to cleave the RNA in the duplex, the RNase H1
catalytic domain needs at least 5 consecutive DNA/RNA base pairs, and cleavage usually
occurs within 7–10 nucleotides from the 5’-end of the RNA. After cleavage, the exposed
phosphate on the 5’-end and hydroxyl on the 3’-end are recognized, and the RNA is subse‐
quently degraded by cellular nucleases. At some point after RNase H1 cleaves the RNA, the
ssASO is released and is available to reengage another transcript.
Even though much progress has been made in the ASO field so far, there are still many
questions that might result in nonspecific effects. One of the principle challenges for success
is efficacious delivery to target organs. Because initial ASO molecules are either of low affinity
or low membrane permeability, they suffered from poor solubility and rapid degradation by
nucleases. In the field, many studies to improve the therapeutic potential of ASOs have focused
on chemical modifications to either improve nuclease resistance, such as 2’-O-methoxyethyl
(2’-MOE), or to facilitate cellular uptake, like phosphorothioate backbone that improves
membrane penetration [55, 56]. Moreover, too many heparin-binding cell surface proteins have
been identified to bind the phosphorothioate oligo with nanomolar affinity. The delivery of
ASO drug, encapsulating with materials ranging from cationic lipids to dendrimers to alginate/
chitosan nanoparticles, has reached new heights of clinical acceptance [52].
Over the past several years, antisense oligonucleotide-based targeted therapy has emerged
rapidly. Interest in the field has ramped-up dramatically, as numerous ongoing clinical trials
are evaluating the treatment effect on diseases with ASOs. Antisense oligonucleotide sodium
LY2181308 (LY2181308), hybridizing to the human survivin mRNA, is well tolerated in
patients with acute myeloid leukemia (AML). In combination with chemotherapy, LY2181308
does not cause additional toxicity, though 1/16 patients had incomplete responses, and 4/16
patients had cytoreduction [57]. Thus, future clinical trials are needed to further confirm its
clinical benefit. In another open-label, parallel-group study, reducing factor XI levels by a
second-generation antisense oligonucleotide FXI-ASO (ISIS 416858) is an effective method for
prevention of postoperative venous thromboembolism. With respect to the risk of bleeding,
FXI-ASO received once daily appeared to be safe [58]. In another phase II trial, compared with
those who received placebo, the participants with Crohn’s disease who received SMAD7 ASO
Mongersen (formerly GED0301) had significantly higher rates of remission and clinical
response [59]. Even more important, mipomersen, an antisense agent targeted to apolipopro‐
tein B, has recently received FDA (United States Food and Drug Administration) approval for
the treatment of familial hypercholesterolemia (http://www.fda.gov/newsevents/newsroom/
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pressannouncements/ucm337195.htm). This compelling therapeutic potential powerfully
supports further clinical investigations of ASOs in subjects in the near future.
5. Ribozymes
Ribozymes, also termed catalytic RNA, are highly structured RNA sequences that can be
engineered to specifically cleave target RNA molecules, similar to the action of protein
enzymes. However, unlike protein ribonucleases, ribozymes cleave only at a specific location,
using base-pairing and tertiary interactions to help align the cleavage site within the catalytic
core. The general mechanism of ribozymes is as follows: a 2’-oxygen nucleophile attacks the
adjacent phosphate in the target RNA backbone, resulting in cleavage products with 2’, 3’-
cyclic phosphate and 5’ hydroxyl termini [60].
Since ribozymes were accidentally discovered in 1982, it has been shown that RNA can act in
at least two ways in biology: as genetic material and as a biological catalyst. Examples of
ribozymes include the hammerhead ribozyme, the Leadzyme, and the hairpin ribozyme. In
the last several years, crystal structures of these ribozymes have been determined, providing
detailed views of the tertiary folds of these RNAs [60, 61], which would be modulated
allosterically to increase specificity of ribozyme action.
Compared to other therapeutical RNAs such as siRNAs, the current therapeutic efficacy of
ribozymes remains low due to their limited specificity, and structural instability [62]. And
furthermore, the amount of free Mg2+ in the intracellular environment plays a critical limitation
role for the catalytic activity [63]. To date, gene-therapy-based studies have focused upon
developing strategies to stabilize ribozymes and transfect them into live cells. Rouge et al.
reported the concept of ribozyme-spherical nucleic acid (SNA) conjugates and found that these
conjugates could allow high cellular uptake of ribozymes, with favorable catalytic activity and
stability [64]. Paudel et al. studied the effect of molecular crowding agents, like polyethylene
glycol (PEG), on the folding and catalysis of ribozymes. They demonstrated that PEG favors
the formation of the docked structure, which increases ribozymes’ activity. In addition, Mg2+-
induced folding in the presence of PEG occurs at concentrations ∼  7-fold lower than in the
absence of PEG [65].
Up to now, at least two clinical trials have positively showed the safety, feasibility, and long-
term stability of using ribozymes targeted to different mRNAs, such as HIV (human immu‐
nodeficiency virus) elements [66] and VEGF-1 [67]. However, the transduction efficiency left
room for improvement. In a phase II cell-delivered gene transfer clinical trial, 74 HIV-1 infected
adults enrolled randomly received a tat/vpr specific ribozyme OZ1 or placebo. This study
showed that OZ1-based gene therapy is safe, and has modest efficacy. In the future, modifi‐
cations would aim to increase the lymphocyte recovery in order to enhance the therapeutic
effect [68]. Another phase II trial of RPI.4610, an antiangiogenic ribozyme targeting the
VEGFR-1 mRNA, also demonstrated a well-tolerated safety profile but lacked the clinical
efficacy, which results in precluding this drug from further development [69]. Thus, insuffi‐
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cient success suggests that further investigation of allosteric regulation is essential to advance
the drug development.
6. Aptamers
Aptamers, single-stranded deoxyribonucleic acid or ribonucleic acid oligonucleotides, are
generated by an in vitro selection process called SELEX (systematic evolution of ligands by
exponential  enrichment).  They can bind their  target  molecules  with high specificity and
selectivity, indicating the probable therapeutic and diagnostic applications for diseases like
cancer, inflammatory diseases, etc. [70, 71]. Because aptamers contain some advantages over
antibodies  and  other  conventional  small-molecule  therapeutics,  such  as  high  specificity,
flexible modification, and low adverse effect, they have been shown as a valuable substi‐
tute to protein antibodies [72].  Moreover,  the strategies developed to chemically modify
backbone can further improve affinity and bioavailability of aptamers [73]. Higher affinity
and specificity could be simultaneously achieved by the genetic-algorithms-based ISM (in
silico maturation) [74].
The properties above have paved the way to further studies on introduction of aptamers to
preclinical and clinical applications. Based on previous data showing antitumor activity of
AS1411, a first-in-class quadruplex DNA aptamer targeting nucleolus, a phase II trial found
that AS1411 appears to have dramatic and durable responses in enrolled patients with
metastatic renal cell carcinoma, even though about 34% participants have AS1411-related mild
adverse events [75]. Malik et al. further discovered that AS1411-linked gold nanospheres
(AS1411-GNS) could markedly promote superior cellular uptake by cancer cells and increase
antiproliferative/cytotoxic effects, with no signs of toxicity [76]. Likewise, other clinical trials
on aptmers targeting FIX (Coagulation Factor IX) [77], vWF (von Willebrand factor) [78], and
TFPI (tissue factor pathway inhibitor) [79] respectively, all show that aptamers are well
tolerated, safe, and represent a new promising target therapy. However, as for some side
effects, further clinical investigations are warranted to better define the clinical indications,
safety, efficacy, and optimal dosing strategy.
7. Decoys
Unlike antisense oligonucleotide approaches that target mRNA, decoys are short, double-
stranded DNA molecules that compete with specific binding sites of transcription factors to
prevent their binding at target promoters, in order to inhibit gene expression at pretranscrip‐
tion level. Since decoys are DNA, they are more stable and easy to handle than RNA-based
intervention strategies [80]. Some methods, including the locked nucleic acid (LNA) intro‐
duced at the 3’-end [81] and chimeric decoys containing discrete binding sites [82], can increase
decoys nuclease resistance and specificity. So far, numerous of studies have indicated that
decoys are suited for novel potential therapeutic for combating cancer [80] and infectious
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diseases [83]. NOTCH1 decoy, a human IgG Fc consisting Notch1 extracellular domain inhibits
tumor angiogenesis and growth by blocking Jagged-dependent activation of Notch signaling.
Although well tolerated to mice for three weeks, NOTCH1 decoy treatment causes adverse
severe gastrointestinal effects [84]. As above, the STAT3 (signal transducers and activators of
transcription 3) decoy oligonucleotide represents another possible single-agent approach to
targeting both the tumor and vascular compartments in murine tumor xenografts mediated
through the inhibition of both STAT3 and STAT1 [85, 86]. Collectively, these findings point to
decoys as highly attractive agents in gene-targeted therapy.
8. Concluding remarks
Gene-targeting strategies based on nucleic acid have opened a new era with the development
of potent and effective gene intervention techniques, such as DNAzymes, ribozymes, siRNA,
ASOs, aptamers, decoys, etc. It is demonstrated that these technologies have versatility and
potency in disrupting pathophysiologically important pathways by silencing the target gene
with relative specificity in vivo and in vitro. Numerous investigative works by several labora‐
tories have been made in these fields. Although some clinical trials have proved the effective‐
ness of these techniques, only a few antisense drugs have been approved by the FDA for clinical
purposes. The main difficulties on the way to develop successful nucleic acid drugs are as
follows: how to ensure efficient and controlled delivery, prolonged target-specific action, and
no adverse effects. If the challenges outlined above can be overcome, these molecules would
prove to be valuable agents for economical and practical new therapies for diseases in the near
future.
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